SFO
GILD icon

Stenger Family Office’s Gilead Sciences GILD Stock Holding History

Stenger Family Office’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Buy
3,494
+22
+0.6% +$2.9K 0.07% 91
2026
Q1 		$484K Buy
3,472
+21
+0.6% +$2.94K 0.09% 91
2025
Q4 		$424K Buy
3,451
+22
+0.6% +$2.67K 0.09% 85
2025
Q3 		$413K Buy
3,429
+24
+0.7% +$2.73K 0.08% 89
2025
Q2 		$391K Buy
+3,405
New +$362K 0.1% 83
2024
Q4 		$310K Buy
+3,357
New +$302K 0.11% 82

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stenger Family Office's GILD Position: Q2 2026 in Review

Stenger Family Office increased its Gilead Sciences (GILD) stake by 0.63% in Q2 2026, buying an estimated $2.9K and bringing the position to 3,494 shares worth $441K. The position accounts for 0.07% of the portfolio, ranked #91.

Stenger Family Office first reported a position in GILD in Q4 2024 and has held it in 6 quarters since. The position peaked at $484K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Stenger Family Office held 3,494 shares of Gilead Sciences worth $441K as of Q2 2026.
  • Stenger Family Office bought 22 Gilead Sciences shares in Q2 2026, an estimated $2.9K.
  • Gilead Sciences made up 0.07% of Stenger Family Office's portfolio in Q2 2026, its #91 holding.
  • Stenger Family Office first reported a position in Gilead Sciences in Q4 2024 and has held it in 6 quarters since.
  • Stenger Family Office's Gilead Sciences position peaked at $484K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Stenger Family Office's 13F filing for Q2 2026, filed 13 Jul 2026.